Astrocyte Reactions to Optic Nerve Damage
Principal Investigator
Tatjana Jakobs, MD
The Schepens Eye Research Institute, Mass. Eye and Ear
Boston, MA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 2009 - June 30, 2010
Grant ID
G2009021
Acknowledgement
Goals
The optic nerve is damaged in glaucoma which interrupts the communication of the eye with the brain. Non-neuronal (glial) cells in the optic nerve may be directly involved, either by harming the nerve fibers, or by protecting them. It is therefore important to understand the role of these cells in glaucoma more fully.
Summary
In glaucoma, ganglion cells – the only retinal neurons that send axons to the brain – are damaged and eventually degenerate, leading to vision loss. Recent research suggests that the first insult to ganglion cells happen at the junction where their axons leave the eye and form the optic nerve. In this place, supporting non-neuronal cells (astrocytes) closely contact the nerve fibers, and the behavior of these astrocytes is clearly altered in glaucoma. But are these changes helpful or harmful? The answer to this question will indicate whether inhibiting or stimulating astrocyte function is a viable therapeutic approach to prevent vision loss. We have proposed two specific aims: (1) it is important to better understand the function of optic nerve astrocytes, in particular their reactions to increased intraocular pressure and nerve damage. For this purpose, a mouse strain will be used that develops glaucoma and shows individual astrocytes with a brightly fluorescent label. This allows observing these cells directly at a level of detail that is not possible with more conventional staining techniques. (2) To answer the question whether astrocytes are helpful or harmful, it is important to know the timeline of events in the optic nerve. If astrocytes show signs of disease before the nerve fibers do, it would suggest that they are harmful. If it is the other way around, they are more likely to play a protective role.
Related Grants
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
National Glaucoma Research
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine